Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionD.B. Root & Company, LLC
Latest Disclosed Ownership654 shares
Latest Disclosed Value $ 292,037
D.B. Root & Company, LLC reports 19.56% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 12, 2026 - D.B. Root & Company, LLC filed a 13F-HR form disclosing ownership of 654 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $292,037 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 813 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -19.56% during the quarter. The current value of the position is $280,134 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 654 -159 -19.56 292 -20.65 0.0698
2026-02-03 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 813 -144 -15.05 369 -1.60 0.0899
2025-11-06 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 957 -125 -11.55 375 -22.25 0.0951
2025-07-22 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,082 -27 -2.43 482 -10.43 0.1422
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,109 242 27.91 538 53.87 0.1736
2025-01-17 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 867 -44 -4.83 349 -17.49 0.1110
2024-10-31 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 911 -124 -11.98 424 -12.78 0.1396
2024-07-15 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,035 -359 -25.75 485 -16.67 0.1655
2024-04-17 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,394 26 1.90 583 4.68 0.1969
2024-01-16 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,368 -162 -10.59 557 4.51 0.2018
2023-11-03 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,530 -12 -0.78 532 -1.85 0.2074
2023-07-18 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,542 57 3.84 543 16.06 0.2053
2023-04-18 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,485 20 1.37 468 10.40 0.1841
2023-01-27 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,465 -28 -1.88 423 -2.08 0.1787
2022-10-26 2022-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,493 183 13.97 432 17.07 0.1967
2022-07-21 2022-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,310 -1,964 -59.99 369 -56.79 0.1583
2022-05-06 2022-03-31 13F Vertex Pharmaceuticals COM 92532F100 3,274 -595 -15.38 854 0.59 0.3179
2022-02-01 2021-12-31 13F Vertex Pharmaceuticals COM 92532F100 3,869 -64 -1.63 849 19.07 0.3061
2021-10-22 2021-09-30 13F Vertex Pharmaceuticals COM 92532F100 3,933 -770 -16.37 713 -24.79 0.2781
2021-07-28 2021-06-30 13F Vertex Pharmaceuticals COM 92532F100 4,703 -64 -1.34 948 -7.42 0.3540
2021-05-04 2021-03-31 13F Vertex Pharmaceuticals COM 92532F100 4,767 2,348 97.06 1,024 79.33 0.4025
2021-02-09 2020-12-31 13F Vertex Pharmaceuticals COM 92532F100 2,419 2,419 571 0.2280
2020-04-29 2020-03-31 13F Vertex Pharmaceuticals COM 92532F100 0 -1,375 -100.00 0 -100.00
2020-01-14 2019-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,375 -15 -1.08 301 28.09 0.1326
2019-10-28 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,390 -780 -35.94 235 -40.81 0.1095
2019-07-19 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 2,170 455 26.53 397 26.03 0.1759
2019-04-12 2019-03-31 13F Vertex Pharmaceuticals Stock 92532F100 1,715 135 8.54 315 20.23 0.1345
2019-01-25 2018-12-31 13F/A-1 Vertex Pharmaceuticals Stock 92532F100 1,580 -189 -10.68 262 -23.17 0.1303
2019-01-24 2018-12-31 13F Vertex Pharmaceuticals Stock 92532F100 1,769 0 341 0.1502
2018-11-05 2018-09-30 13F Vertex Pharmaceuticals Stock 92532F100 1,769 154 9.54 341 24.45 0.1502
2018-07-25 2018-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 1,615 30 1.89 274 6.20 0.1293
2018-05-02 2018-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 1,585 1,585 258 0.1362
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.